3 compelling ASX shares to buy in February

Are you planning to make some new additions to your portfolio in the near future? If you are, then you might want to take a look at the ones listed below.

Here’s why they have been tipped as ASX shares to buy: 

The first ASX share to look at is CSL. This biotechnology giant is is made up of two businesses, CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. The CSL share price has come under pressure this year due to plasma collection headwinds. While this is likely to weigh on its growth, UBS appears to believe it is worth dealing with this…